ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sumitomo Pharma America, Inc.
Dana-Farber Cancer Institute
Prelude Therapeutics
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Prelude Therapeutics
Melbourne Health